Department of Translational Proteomics, Institut de Recherches Cliniques de Montréal, Montréal, Canada.
Department of Biochemistry, Molecular Medicine Université de Montréal.
Expert Opin Drug Discov. 2021 Aug;16(8):881-895. doi: 10.1080/17460441.2021.1909566. Epub 2021 Apr 6.
: The COVID-19 pandemic originated from the emergence of anovel coronavirus, SARS-CoV-2, which has been intensively studied since its discovery in order to generate the knowledge necessary to accelerate the development of vaccines and antivirals. Of note, many researchers believe there is great potential in systematically identifying host interactors of viral factors already targeted by existing drugs.: Herein, the authors discuss in detail the only available large-scale systematic study of the SARS-CoV-2-host protein-protein interaction network. More specifically, the authors review the literature on two key SARS-CoV-2 drug targets, the Spike surface glycoprotein, and the RNA polymerase. The authors also provide the reader with their expert opinion and future perspectives.: Interactions made by viral proteins with host factors reveal key functions that are likely usurped by the virus and, as aconsequence, points to known drugs that can be repurposed to fight viral infection and collateral damages that can exacerbate various disease conditions in COVID-19.
: COVID-19 大流行源于一种新型冠状病毒 SARS-CoV-2 的出现,自发现以来,人们对其进行了深入研究,以获取加速疫苗和抗病毒药物开发所需的知识。值得注意的是,许多研究人员认为,系统地确定已被现有药物靶向的病毒因子的宿主相互作用因子具有巨大潜力。: 本文作者详细讨论了唯一一项针对 SARS-CoV-2 宿主蛋白-蛋白相互作用网络的大规模系统研究。更具体地说,作者回顾了关于 SARS-CoV-2 的两个关键药物靶点的文献,即刺突表面糖蛋白和 RNA 聚合酶。作者还为读者提供了他们的专家意见和未来展望。: 病毒蛋白与宿主因子的相互作用揭示了关键功能,这些功能很可能被病毒篡夺,因此,这也指向了可以重新用于对抗病毒感染和可能加重 COVID-19 中各种疾病状况的并发症的已知药物。